Compare VWAV & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VWAV | KPTI |
|---|---|---|
| Founded | 2024 | 2008 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.0M | 172.6M |
| IPO Year | N/A | 2013 |
| Metric | VWAV | KPTI |
|---|---|---|
| Price | $7.28 | $8.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 234.3K | ★ 783.7K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $46.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $2.06 | $3.51 |
| 52 Week High | $15.80 | $10.99 |
| Indicator | VWAV | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 52.67 |
| Support Level | $6.80 | $5.60 |
| Resistance Level | $8.70 | $8.95 |
| Average True Range (ATR) | 0.58 | 0.69 |
| MACD | 0.03 | -0.19 |
| Stochastic Oscillator | 29.75 | 26.19 |
VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).